Oppenheimer Maintains Outperform on Pliant Therapeutics, Lowers Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones maintains an Outperform rating on Pliant Therapeutics (NASDAQ:PLRX) but lowers the price target from $48 to $45.
August 08, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer analyst Jeff Jones maintains an Outperform rating on Pliant Therapeutics but lowers the price target from $48 to $45.
The Outperform rating suggests continued confidence in the stock's performance, but the lowered price target indicates a slightly less optimistic outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100